comparemela.com

Latest Breaking News On - Shenzhen chipscreen biosciences co ltd - Page 1 : comparemela.com

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

/PRNewswire/ Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company s lead innovative.

Feng wangUnited statesRuihua xuSun yatXianping luChidamide tucidinostatChipscreen biosciencesWeili zhaoChidamide epidazaData monitoring committeeChipscreen biosciences united states co ltdPrnewswire shenzhen chipscreen biosciences co ltdChengdu small molecule early rd centerShanghai jiao tong university school of medicineChengdu regional head office rd centerShenzhen chipscreen biosciences co ltd

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

/PRNewswire/ Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that on January 5, 2024, the dosing of the first patient for a phase I.

Hong kongUnited statesSan franciscoChipscreen newway biosciencesChipscreen newwayHaimen jiangsuChipscreen biosciencesChipscreen biosciences united statesShenzhen chipscreen pharmaceuticals co ltdShanghai business centerBiocytogen pharmaceuticals beijing co ltdPrnewswire chengdu chipscreen newway biosciences co ltdShenzhen chipscreen biosciences co ltdSun yat sen university cancer centerChengdu chipscreen pharmaceuticals co ltdEucure beijing biopharma co ltd

Chipscreen s New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA") through its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd. The notice grants approval for conducting clinical trials of CS32582 capsules in the treatment of psoriasis.

Shenzhen chipscreen biosciences co ltdChengdu chipscreen pharmaceutical coNational medical products administrationAutoimmune diseasesTherapeutic efficacyWholly owned subsidiaryClinical trialOral medicationInflammatory bowel diseaseClinical research center

Biocytogen s Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ( Biocytogen , HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd.

United statesHong kongBaden wübergHaimen jiangsuChipscreen newway biosciencesChipscreen biosciencesYuelei shenEucure biopharmaChipscreen newwayXianping luEucure beijing biopharma co ltdDrug administrationBiocytogen pharmaceuticals beijing co ltdHead of the centerShenzhen chipscreen biosciences co ltdGreater china

Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 (Envafolimab) in combination with.

Hong kongJun chenJinzij wuChipscreen biosciencesLu xianpingShanghai public health clinical centerAscletis bioscience co ltdHong kong stock exchangeAscletis pharma incShenzhen chipscreen biosciences co ltdAscletis pharmaDeputy chief physicianGeneral manager

vimarsana © 2020. All Rights Reserved.